Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 3/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 3/20 | 0.48 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474165 | 0.91 | CCNE2 (0.49) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL16184516 | 0.90 | CCNE2 (0.46) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL16183566 | 0.89 | CYP1A2 (0.47) | CHRNB2CHRNA5CHRNA4ABCB1ABCG2 | |
| SCHEMBL16184654 | 0.89 | ABCG2 (0.46) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL16184626 | 0.87 | ABCG2 (0.42) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL16184669 | 0.87 | USP2 (0.46) | CHRNB2CHRNA5CHRNA4ABCB1ABCG2 | |
| SCHEMBL16184487 | 0.87 | ABCB1 (0.43) | CCNE2CCNE1CDK2CDK4CCND1 | |
| SCHEMBL16184665 | 0.87 | RXFP1 (0.43) | CHRNB2CHRNA5CHRNA4ABCB1ABCG2 | |
| SCHEMBL16184679 | 0.86 | USP2 (0.44) | CHRNB2CHRNA5CHRNA4ABCB1ABCG2 | |
| SCHEMBL16184666 | 0.85 | ABCB1 (0.48) | CHRNB2CHRNA5CHRNA4ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | CCNE2 4641/4885CCNE1 4118/4885CDK2 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.